Lund, Sweden, 2014-10-23 08:39 CEST (GLOBE NEWSWIRE) --
The BSI-symposium arranged by EXINI and FUJIFILM RI Pharma at the annual EANM-congress (European Association of Nuclear Medicine) held in Gothenburg this week, drew attention to the utilization of the imaging biomarker Bone Scan Index (BSI) in daily clinical workflow and management of new therapies and treatment methods for metastatic prostate cancer.
”BSI is easy to understand for both doctors and patients. Integrating the BSI-value into daily clinical workflow is easy and Bone Scan Index also proves useful in assessing efficiency of new therapies, such as Radium 223, when treating metastatic castration-resistant prostate cancer”, says Dr. Jens Kurth, University of Rostock
”We are facing a new paradigm presenting us with a variety of treatment methods for mCRPC to choose from. These call for us to be able to more closely identify the single most suitable method for each individual patient. One of the more difficult tasks is to assess the extent of the patient’s condition, hence the need for a quantitative method measuring metastatic burden before and during treatment distributing new therapies and isotopes. BSI offers such a quantifiable method and is easily integrated with other biomarkers in prognostic models ”, concludes Professor Anders Bjartell, Dept. of Urology, Skåne Academic Hospital.
”Facing an auditorium filled with international nuclear medicine physicians is encouraging. The sheer numbers and background of the attendees indicate a considerable demand for an effective imaging biomarker in the care for patients suffering advanced prostate cancer. For EXINI, this is an acknowledgement of our investment in BSI and the software EXINI boneBSI, telling us we are addressing a growing demand correctly”, comments Magnus Aurell, CEO, EXINI Diagnostics AB.
Moreover Bone Scan Index (BSI):
BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnosis and stratification and the monitoring of treatment response. It also provides increased accuracy in prognoses involving patients suffering from skeletal metastases originating from prostate- or breast cancer.
What is more, BSI has demonstrated its importance in the process of developing new drugs, thus proving itself just as important for clinical use as for the pharmaceutical industry. EXINI boneBSI is the only software capable of extracting BSI-values for both these purposes.
www.bonescanindex.org
www.bonescanindex.org/meetings-and-congresses/ > EANM Congress 2014
http://exini.com/software/exini-bone-bsi/
www.eanm.org
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
